Phase I study of concurrent bevacizumab (Avastin) with involved-field thoracic radiotherapy for inoperable non-squamous non-small cell lung cancer, followed by both concurrent and maintenance bevacizumab
Phase of Trial: Phase I
Latest Information Update: 01 Jun 2011
At a glance
- Drugs Bevacizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 04 Apr 2011 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov. Trial terminated due to toxicity.
- 03 Oct 2007 New trial record.